Ashby technique

Last updated
Visual Model of Ashby Technique. Ashbytech.svg
Visual Model of Ashby Technique.

The Ashby technique is a method for determining the volume and life span of red blood cells in humans, first published by Dr. Winifred Ashby in 1919. [1] The technique involves injection of compatible donor red blood cells of a different blood group into a recipient, followed by blood testing periodically afterwards. Differential agglutination of the red cells is then used to determine the number of remaining donor cells, allowing the survival rate to be determined. It does not involve radioisotope technology, and was the first technique to successfully establish the correct red blood cell life span. In particular, Type O blood is first transfused into Type A or B subjects. In subsequent blood samples, the patient's own A and B blood cells are removed by agglutination with either anti-A or anti-B serum. The number of remaining nonagglutinated Type O cells as a function of time defines the survival rate of blood cells. [2] This technique was used extensively during World War II and shortly after but has more recently been replaced by techniques that label one's own blood, due of the dangers of using donor blood. [3]

Related Research Articles

Blood type Classification of blood based on antibodies and antigens on red blood cell surfaces

A blood type is a classification of blood, based on the presence and absence of antibodies and inherited antigenic substances on the surface of red blood cells (RBCs). These antigens may be proteins, carbohydrates, glycoproteins, or glycolipids, depending on the blood group system. Some of these antigens are also present on the surface of other types of cells of various tissues. Several of these red blood cell surface antigens can stem from one allele and collectively form a blood group system.

Blood transfusion Intravenous transference of blood products

Blood transfusion is the process of transferring blood products into a person's circulation intravenously. Transfusions are used for various medical conditions to replace lost components of the blood. Early transfusions used whole blood, but modern medical practice commonly uses only components of the blood, such as red blood cells, white blood cells, plasma, clotting factors and platelets.

A blood bank is a center where blood gathered as a result of blood donation is stored and preserved for later use in blood transfusion. The term "blood bank" typically refers to a division of a hospital where the storage of blood product occurs and where proper testing is performed. However, it sometimes refers to a collection center, and some hospitals also perform collection. Blood banking includes tasks related to blood collection, processing, testing, separation, and storage.

Hemagglutination assay

The hemagglutination assay or haemagglutination assay (HA) and the hemagglutination inhibition assay were developed in 1941–42 by American virologist George Hirst as methods for quantifying the relative concentration of viruses, bacteria, or antibodies.

Agglutination (biology) Type of antibody response

Agglutination is the clumping of particles. The word agglutination comes from the Latin agglutinare.

Interleukin 5 Protein-coding gene in the species Homo sapiens

Interleukin 5 (IL5) is an interleukin produced by type-2 T helper cells and mast cells.

Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to an insufficient number of oxygen-carrying red blood cells in the circulation. The lifetime of the RBCs is reduced from the normal 100–120 days to just a few days in serious cases. The intracellular components of the RBCs are released into the circulating blood and into tissues, leading to some of the characteristic symptoms of this condition. The antibodies are usually directed against high-incidence antigens, therefore they also commonly act on allogenic RBCs. AIHA is a relatively rare condition, with an incidence of 5-10 cases per 1 million persons per year in the warm-antibody type and 0.45 to 1.9 cases per 1 million persons per year in the cold antibody type. Autoimmune hemolysis might be a precursor of later onset systemic lupus erythematosus.

Francis Peyton Rous American scientist (1879-1970)

Francis Peyton Rous was an American pathologist at the Rockefeller University known for his works in oncoviruses, blood transfusion and physiology of digestion. A medical graduate from the Johns Hopkins University, he was discouraged to become a practicing physician due to severe tuberculosis. After three years of working as an instructor of pathology at the University of Michigan, he became dedicated researcher at the Rockefeller Institute for Medical Research for the rest of his career.

CLEC4C is a membrane protein of plasmacytoid dendritic cells used as a marker for this kind of cells and denoted as CD303 in the nomenclature of the Cluster of differentiation.

ITGAE

Integrin, alpha E (ITGAE) also known as CD103 is an integrin protein that in human is encoded by the ITGAE gene. CD103 binds integrin beta 7 to form the complete heterodimeric integrin molecule αEβ7, which has no distinct name. The αEβ7 complex is often referred to as "CD103" though this strictly refers only to the αE chain. Note that the β7 subunit can bind with other integrin α chains, such as α4 (CD49d).

Leukotriene B<sub>4</sub> receptor 1

Leukotriene B4 receptor 1 is a protein that in humans is encoded by the LTB4R gene.

B-cell linker

The B-cell linker protein is encoded by the BLNK gene and is an adaptor protein also known as SLP-65, BASH, and BCA. BLNK is expressed in B cells and macrophages and plays a large role in B cell receptor signalling, in a fashion analogous to the role its paralogue SLP-76 plays in T cell receptor signalling. As it has no known intrinsic enzymatic activity, the function of BLNK is to temporally and spatially coordinate and regulate signalling effectors downstream of the B cell receptor.

IGLL1

Immunoglobulin lambda-like polypeptide 1 is a protein that in humans is encoded by the IGLL1 gene. IGLL1 has also recently been designated CD179B.

NCR1 Mammalian protein found in Homo sapiens

Natural cytotoxicity triggering receptor 1 is a protein that in humans is encoded by the NCR1 gene. NCR1 has also been designated as CD335 (cluster of differentiation, NKP46, NKp46, NK-p46, and LY94.

DAPP1

Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide is a protein that in humans is encoded by the DAPP1 gene.

TRAT1

T-cell receptor-associated transmembrane adapter 1 is a protein that in humans is encoded by the TRAT1 gene.

Megakaryocyte–erythroid progenitor cell

The megakaryocyte–erythroid progenitor cell is a cell that gives rise to megakaryocytes and erythrocytes.

Transitional B cells are B cells at an intermediate stage in their development between bone marrow immature cells and mature B cells in the spleen. Primary B cell development takes place in the bone marrow, where immature B cells must generate a functional B cell receptor (BCR) and overcome negative selection induced by reactivity with autoantigens. Transitional cells can be found in the bone marrow, peripheral blood, and spleen, and only a fraction of the immature B cells that survive after the transitional stage become mature B cells in secondary lymphoid organs such as the spleen.

<i>Women of Mayo Clinic</i>

Women of Mayo Clinic: The Founding Generation is a 2016 non-fiction book by Virginia M. Wright-Peterson, chronicling the individual contributions of professional women who helped establish and develop the Mayo Clinic in Rochester, Minnesota. Covering a period of 60 years, the Sisters of Saint Francis of Rochester, Minnesota worked in conjunction with the Mayo family to open a hospital that would accept patients of all faiths. Beginning with a 27-bed facility, the women physicians and other medical professionals would eventually serve in theaters of war, and create an environment that evolved according to patient needs. Wright-Peterson is a faculty member of the University of Minnesota Rochester, and a former Mayo Clinic administrator.

Blood compatibility testing Testing to identify incompatibilities between blood types

Blood compatibility testing is conducted in a medical laboratory to identify potential incompatibilities between blood types in blood transfusion. It is also used to diagnose and prevent some complications of pregnancy that can occur when the baby has a different blood group from the mother. Blood compatibility testing includes blood typing, which detects the antigens on red blood cells that determine a person's blood type; testing for unexpected antibodies against blood group antigens ; and, in the case of blood transfusions, mixing the recipient's plasma with the donor's red blood cells to detect incompatibilities (crossmatching). Routine blood typing involves determining the ABO and RhD type, and involves both identification of ABO antigens on red blood cells and identification of ABO antibodies in the plasma. Other blood group antigens may be tested for in specific clinical situations.

References

  1. Winifred, Ashby (1919). "The Determination of the Length of Life of Transfused Blood Corpuscles in Man". J Exp Med. 29 (3): 267–281. doi:10.1084/jem.29.3.267. PMC   2126347 . PMID   19868318.
  2. Franco RS (February 2009). "The measurement and importance of red cell survival". Am. J. Hematol. 84 (2): 109–14. doi: 10.1002/ajh.21298 . PMID   19025796.
  3. Lichtman, Marshall (2005-10-14). Williams Hematology (7th ed.). McGraw-Hill Professional. ISBN   978-0-07-143591-8.

Further reading